title: Quality of life in patients with persistent allergic rhinitis treated with desloratadine monotherapy or desloratadine plus montelucast combination.
abstract: OBJECTIVE
  This study aims to compare the effectiveness of desloratadine monotherapy and desloratadine plus montelukast combination therapy on quality of life in patients with persistent allergic rhinitis.
  
  
  METHODS
  This study consists of 40 patients (28 females, 12 males, mean age 29.8 years; range 17 to 44 years) referred to ear, nose, and throat outpatient clinic between May 2010 and September 2010. A six-week randomized, double-blind, cross-sectional study was performed in two arms: In group 1, 20 patients received desloratadine (5 mg/d) alone; in group 2, 20 patients received desloratadine (5 mg) plus montelukast (10 mg) combination therapy. Quality of life was assessed on the day before starting treatment and on the last day of each treatment period using the Rhinoconjunctivitis Quality of Life Questionnaire and Nighttime Symptom Scores.
  
  
  RESULTS
  In group 1, the mean quality of life scores before and after treatment were 3.17 and 2.43, respectively. In group 2, the mean quality of life scores before and after treatment were 2.94 and 1.73, respectively.
  
  
  CONCLUSIONS
  Desloratadine plus montelukast combination therapy may have a positive impact on quality of life, sleep symptoms in particular.
authors.affiliation: Department of Otolaryngology, Dr. Lütfi Kırdar Kartal Training and Research Hospital, 34890 Cevizli, Kartal, İstanbul, Turkey. banuatalay81@gmail.com.
authors.forename: Banu Atalay
authors.initials: BA
authors.lastname: Erdoğan
authors.forename: Arif
authors.initials: A
authors.lastname: Sanlı
authors.forename: Mustafa
authors.initials: M
authors.lastname: Paksoy
authors.forename: Gökhan
authors.initials: G
authors.lastname: Altın
authors.forename: Sedat
authors.initials: S
authors.lastname: Aydın
mesh_terms: D000085:Acetates / Q000008:administration & dosage*; D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage*; D003430:Cross-Sectional Studies; D003521:Cyclopropanes; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D039563:Histamine H1 Antagonists, Non-Sedating / Q000008:administration & dosage*; D006801:Humans; D020024:Leukotriene Antagonists / Q000627:therapeutic use; D017336:Loratadine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D008297:Male; D011788:Quality of Life; D011804:Quinolines / Q000008:administration & dosage*; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy* / Q000523:psychology; D013440:Sulfides; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000085:Acetates; D018927:Anti-Asthmatic Agents; D003521:Cyclopropanes; D039563:Histamine H1 Antagonists, Non-Sedating; D020024:Leukotriene Antagonists; D011804:Quinolines; D013440:Sulfides; D017336:Loratadine; C121345:desloratadine; C093875:montelukast